[November 19, 2025] Sinew Pharma Co., Ltd. (TPEx: 6634), following its invited presentation at the 9th MASH Drug Development Summit held in Boston, USA this September, has once again received major recognition. Yesterday (18th), the company was honored with the Bronze Award in the Pharmaceutical R&D Category at the 2025 National Drug and Technology Research & Development Awards, jointly organized by the Taiwan Food and Drug Administration (TFDA) and the Industrial Development Administration (IDA). Sinew stood out with its multi-target liver-disease drug candidate SNP-6, marking a significant dual recognition from both international and domestic arenas. The award ceremony was held at the International Conference Hall in Building C of the National Biotechnology Research Park.
The National Drug and Technology Research & Development Award is Taiwan’s only national-level recognition for pharmaceutical R&D co-organized by central government agencies. Established in 2001 by the Department of Pharmaceutical Affairs (then led by Director You-Pu Hu) of the Department of Health under Article 41 of the Pharmaceutical Affairs Act, and co-founded with the Industrial Development Bureau of the Ministry of Economic Affairs, the award aims to honor institutions and enterprises with outstanding achievements in new drug and medical device development. Since its inception, it has been regarded as one of the highest honors in Taiwan’s biotech and pharmaceutical sectors. In its first year, the Gold Award prize reached NT$1 million, symbolizing strong government support for innovative research. Awards are divided into three major categories—Pharmaceuticals, Medical Devices, and Manufacturing Technology—and are further distinguished into Gold, Silver, and Bronze levels based on innovation and impact. As of 2025, over 250 awards have been granted, demonstrating Taiwan’s strong innovation capacity and global competitiveness in biomedical R&D.
Sinew Pharma’s Chairman Kai-Min Chu stated:
“Receiving recognition on an international stage and then winning a national-level award is truly meaningful for our team. The development concept behind SNP-6 is to break the limitations of traditional single-target treatments. Through an integrated multi-target strategy, we simultaneously address metabolic, immune, and fibrotic pathways—opening a new chapter in liver-disease therapeutics.”
In September, Sinew Pharma was invited to present at the MASH Drug Development Summit in Boston, where the company’s principal inventor, Distinguished Professor You-Pu Hu, delivered an oral keynote presentation. The talk highlighted the latest diagnostic and therapeutic findings of Sinew’s SNP-6 series, a promising MASH/NASH candidate, as well as its associated non-invasive biomarkers. The summit is among the most influential global conferences dedicated to MASH drug development, gathering senior executives from major international pharmaceutical companies. Sinew’s invitation to present underscores the growing global attention toward the company’s R&D capabilities.
